Abstract
Suboptimal glycemic control is often associated with albuminuria and decline in estimated GFR (eGFR) in patients with diabetic kidney disease (DKD). Sodium-glucose linked transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors have individually been shown to exert benefit on glycemic control and/or albuminuria in patients with DKD. We assessed the effects of the SGLT2 inhibitor dapagliflozin (dapa) alone and in combination with the DPP4 inhibitor saxagliptin (saxa) on albuminuria and HbA1c in patients with Type 2 diabetes and DKD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
